Clinical Trials
230 trialsCD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
Columbia University
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Memorial Sloan Kettering Cancer Center
MK-3475-G21
Merck Sharp & Dohme LLC
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
National Institutes of Health Clinical Center (CC)
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Spectrum Pharmaceuticals, Inc
R-PMDT Regimen in Newly Diagnosed PCNSL
Institute of Hematology & Blood Diseases Hospital, China
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
M.D. Anderson Cancer Center
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
M.D. Anderson Cancer Center
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma, Inc.
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
Electra Therapeutics Inc.
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
PRIMAVERA
AstraZeneca
xDRIVE for Florida-based Cancer Patients
First Ascent Biomedical Inc.
MK-3475-051
Merck Sharp & Dohme LLC
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
M.D. Anderson Cancer Center
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Memorial Sloan Kettering Cancer Center
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
GLOHRT-01
Huazhong University of Science and Technology
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Memorial Sloan Kettering Cancer Center
CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
Chinese PLA General Hospital
CD70-targeted immunoPET Imaging of Malignant Cancers
RenJi Hospital
DAHLIA
Recursion Pharmaceuticals Inc.
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Eastern Cooperative Oncology Group
OHGW-ACP
Azienda USL Reggio Emilia - IRCCS
EPCOREâ„¢FL-2
Genmab
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Children's Oncology Group
VIWA-1
University of Ulm
REFRACT
University of Birmingham
SISTER
University Medical Center Groningen
GLOBRYTE
Hoffmann-La Roche
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
Lantern Pharma Inc.
Digital Peer Navigation for Adolescents and Young Adults With Cancer
University Health Network, Toronto
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
ModeX Therapeutics, An OPKO Health Company
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
KinLET
ITM Solucin GmbH
Indocyanine Green (ICG) Guided Tumor Resection
St. Jude Children's Research Hospital
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
ASSIST
Massachusetts General Hospital
CD4CAR for CD4+ Leukemia and Lymphoma
Indiana University
Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
Jabez Bioscience, Inc
REALIZE
University of Oklahoma
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
St. Louis University
HOPAYA
Centre Leon Berard
PEACE
Massachusetts General Hospital
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy
University of Nebraska
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Dren Bio